SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+18.01%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.51B
AUM Growth
+$39.9M
(+2.7%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-7.14%
Top 10 Holdings %
Top 10 Hldgs %
65.29%
Holding
64
New
13
Increased
8
Reduced
13
Closed
14
Top Buys
| 1 |
AstraZeneca
AZN
|
$121M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$51.1M |
| 3 |
Idexx Laboratories
IDXX
|
$35.5M |
| 4 |
Exelixis
EXEL
|
$33.1M |
| 5 |
Boston Scientific
BSX
|
$32.9M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$85M |
| 2 |
Eli Lilly
LLY
|
$47.1M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$44.6M |
| 4 |
Biogen
BIIB
|
$36.9M |
| 5 |
Merck
MRK
|
$36.2M |
Sector Composition
| 1 | Healthcare | 99.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLUE
51
DELISTED
bluebird bio
BLUE
| – | – |
-33,641
| Closed | -$2.14M |
|
52
BioMarin Pharmaceuticals
BMRN
$11.3B
| – | – |
-359,035
| Closed | -$34.9M |
|
53
Keros Therapeutics
KROS
$638M
| – | – |
-77,100
| Closed | -$3.29M |
|
54
Kura Oncology
KURA
$732M
| – | – |
-616,169
| Closed | -$7.54M |
|
|
55
Eli Lilly
LLY
$661B
| – | – |
-137,100
| Closed | -$47.1M |
|
56
NovoCure
NVCR
$1.35B
| – | – |
0
| – | – |
|
57
SPDR S&P 500 ETF Trust
SPY
$656B
| – | – |
0
| – | – |
|
58
Sarepta Therapeutics
SRPT
$1.98B
| – | – |
-119,065
| Closed | -$16.4M |
|
59
Travere Therapeutics
TVTX
$1.75B
| – | – |
-1,263,721
| Closed | -$28.4M |
|
|
ISEE
60
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-905,982
| Closed | -$22M |
|
|
RXDX
61
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| – | – |
-123,842
| Closed | -$13.3M |
|
|
HZNP
62
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-408,819
| Closed | -$44.6M |
|
|
CTIC
63
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| – | – |
-2,794,542
| Closed | -$11.7M |
|